Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S G Ellis

Showing results (201-210 of 222) with videos related to

Pageof 23
Sort By:
Journal of the American College of Cardiology|October 1, 1989
Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study GroupE J Topol, S G Ellis, R M Califf, et al.
The American Journal of Cardiology|March 1, 1993
Quantitative analysis of factors influencing late lumen loss and restenosis after directional coronary atherectomyJ J Popma, N B De Cesare, C A Pinkerton, et al.
Circulation|August 1, 1991
Relation of stenosis morphology and clinical presentation to the procedural results of directional coronary atherectomyS G Ellis, N B De Cesare, C A Pinkerton, et al.
Journal of the American College of Cardiology|November 11, 1991
Clinical, angiographic and procedural correlates of quantitative coronary dimensions after directional coronary atherectomyJ J Popma, N B De Cesare, S G Ellis, et al.
Circulation|April 15, 1995
Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT InvestigatorsJ E Tcheng, R A Harrington, K Kottke-Marchant, et al.
Circulation|May 1, 1991
Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction--phase 5 randomized trial. TAMI Study GroupR M Califf, E J Topol, R S Stack, et al.
Circulation|October 3, 2001
Long-term clinical outcomes after unprotected left main trunk percutaneous revascularization in 279 patientsW A Tan, H Tamai, S J Park, et al.
JAMA|August 13, 1997
Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic ComplicationE J Topol, J J Ferguson, H F Weisman, et al.
Circulation|July 6, 2000
Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesionsF A Cura, D L Bhatt, A M Lincoff, et al.
American Heart Journal|March 1, 1997
Influence of local delivery of the protein tyrosine kinase receptor inhibitor tyrphostin-47 on smooth-muscle cell proliferation in a rat carotid balloon-injury modelM Gottsauner-Wolf, Y Jang, A M Lincoff, et al.
Pageof 23

Showing results (201-210 of 222) with videos related to

Sort By:
Pageof 23
Journal of the American College of Cardiology|October 1, 1989
Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study GroupE J Topol, S G Ellis, R M Califf, et al.
The American Journal of Cardiology|March 1, 1993
Quantitative analysis of factors influencing late lumen loss and restenosis after directional coronary atherectomyJ J Popma, N B De Cesare, C A Pinkerton, et al.
Circulation|August 1, 1991
Relation of stenosis morphology and clinical presentation to the procedural results of directional coronary atherectomyS G Ellis, N B De Cesare, C A Pinkerton, et al.
Journal of the American College of Cardiology|November 11, 1991
Clinical, angiographic and procedural correlates of quantitative coronary dimensions after directional coronary atherectomyJ J Popma, N B De Cesare, S G Ellis, et al.
Circulation|April 15, 1995
Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT InvestigatorsJ E Tcheng, R A Harrington, K Kottke-Marchant, et al.
Circulation|May 1, 1991
Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction--phase 5 randomized trial. TAMI Study GroupR M Califf, E J Topol, R S Stack, et al.
Circulation|October 3, 2001
Long-term clinical outcomes after unprotected left main trunk percutaneous revascularization in 279 patientsW A Tan, H Tamai, S J Park, et al.
JAMA|August 13, 1997
Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic ComplicationE J Topol, J J Ferguson, H F Weisman, et al.
Circulation|July 6, 2000
Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesionsF A Cura, D L Bhatt, A M Lincoff, et al.
American Heart Journal|March 1, 1997
Influence of local delivery of the protein tyrosine kinase receptor inhibitor tyrphostin-47 on smooth-muscle cell proliferation in a rat carotid balloon-injury modelM Gottsauner-Wolf, Y Jang, A M Lincoff, et al.
Pageof 23